MSB Trading 2020 - a new dawn, page-10038

Bit of bounce, can it get back to pre-vaccine of 3.38, sellers trying to wall it at 3.35.
So the "overwhelming efficacy" carried forwrd from the Mt Sinai results has not been shown....surely a 75% success would warrant "efficacy".
An interim analysis compares randomised arms at any time point before the end of a phase 3 trial and usually occurs before recruitment is complete. It is especially appealing to the regulatory agencies and the sponsor, allowing for decisions and changes to be made in the middle of the study.The analysis provides several options and opportunities for the trial, for example:
An opportunity to re-estimate the sample size - unchanged
An opportunity to modify the trial design - unchanged
An option to stop the trial for efficacy or futility - neither was demonstrated?
An option to continue the trial as originally planned.- was agreed